sjg-136

Small moleculeexperimental

Clinical trial activity

4 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Nov 1, 2004 (NCT00103220)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • DNACROSS-LINKING AGENT

    DNA cross-linking agent

Chemistry & pharmacology

Loading structure…

SMILES

C=C1C[C@H]2C=Nc3cc(OCCCOc4cc5c(cc4OC)C(=O)N4CC(=C)C[C@H]4C=N5)c(OC)cc3C(=O)N2C1
Mol. weight
556.62 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5h-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione)
  • nsc694501
  • nsc 694501
  • nsc-694501
  • sjg136
  • sjg 136
  • sjg-136
  • sjg-136
  • sjg-136
  • sjg-136
  • uglydimer1 cpd

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01200797Phase 2Jul 1, 2010National Cancer Institute (NCI), University of South Florida
NCT00301769Phase 1Dec 1, 2005National Cancer Institute (NCI), University of Texas at Houston
NCT00121290Phase 1Feb 1, 2005National Cancer Institute (NCI), Vanderbilt University
NCT00103220Phase 1Nov 1, 2004Cornell University, National Cancer Institute (NCI)
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government4422004
Cornell UniversityAcademic/Hospital1012004
University of South FloridaAcademic/Hospital1012010
University of Texas at HoustonAcademic/Hospital1012005
Vanderbilt UniversityAcademic/Hospital1012005
5 organizations
Page 1 / 1